Thorsten Simon
Overview
Explore the profile of Thorsten Simon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
3409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lozano-Montoya J, Jimenez-Pastor A, Fuster-Matanzo A, Weiss G, Cerda-Alberich L, Veiga-Canuto D, et al.
Front Oncol
. 2025 Mar;
15:1528836.
PMID: 40061893
Introduction: Neuroblastoma, the most prevalent solid cancer in children, presents significant biological and clinical heterogeneity. This inherent heterogeneity underscores the need for more precise prognostic markers at the time of...
2.
Flaadt T, Rehm J, Simon T, Hero B, Ladenstein R, Lode H, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796776
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae,...
3.
van Zogchel L, Decarolis B, van Wezel E, Zappeij-Kannegieter L, Gelineau N, Schumacher-Kuckelkorn R, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):331.
PMID: 39722049
Background: Liquid biopsies offer less burdensome sensitive disease monitoring. Bone marrow (BM) metastases, common in various cancers including neuroblastoma, is associated with poor outcomes. In pediatric high-risk neuroblastoma most patients...
4.
Danzer M, Faldum A, Simon T, Hero B, Schmidt R
Biom J
. 2024 Oct;
66(7):e202300181.
PMID: 39402846
The analysis of multiple time-to-event outcomes in a randomized controlled clinical trial can be accomplished with existing methods. However, depending on the characteristics of the disease under investigation and the...
5.
Toenne R, Kristiment R, Waack K, Schneider D, Simon T, Reinhardt D
Klin Padiatr
. 2024 Sep;
PMID: 39284575
Background: In the period from 2019 to 2022, pediatric hemato-oncological patients were cared for in a pilot project in North Rhine-Westphalia (NRW). The project delivered care at the homes of...
6.
Espinoza A, Bagatell R, McHugh K, Naranjo A, Van Ryn C, Rojas Y, et al.
Pediatr Blood Cancer
. 2024 Jul;
71(10):e31218.
PMID: 39072986
Background: Image-defined risk factors (IDRFs) were promulgated for predicting the feasibility and safety of complete primary tumor resection in children with neuroblastoma (NB). There is limited understanding of the impact...
7.
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, et al.
Lancet Oncol
. 2024 Jun;
25(7):922-932.
PMID: 38936379
Background: Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST)...
8.
Junger S, Ruess D, Kabbasch C, Gielen G, Pietsch T, Johann P, et al.
Neurooncol Pract
. 2024 Mar;
11(2):216-218.
PMID: 38496916
No abstract available.
9.
Stucke I, Morgenstern D, Diendorfer G, Mayr G, Pichler H, Schulz W, et al.
J Geophys Res Atmos
. 2024 Mar;
129(1):e2023JD039505.
PMID: 38440118
Upward lightning (UL) has become a major threat to the growing number of wind turbines producing renewable electricity. It can be much more destructive than downward lightning due to the...
10.
Stucke I, Morgenstern D, Diendorfer G, Mayr G, Pichler H, Schulz W, et al.
J Geophys Res Atmos
. 2024 Mar;
128(10):e2022JD037776.
PMID: 38439996
Upward lightning is rarer than downward lightning and requires tall (100+ m) structures to initiate. It may be either self-initiated or triggered by other lightning discharges. While conventional lightning location...